Trastuzumab, a monoclonal antibody targeting epidermal growth factor receptor 2 (HER2) in breast cancer [12], was also among the promising therapeutic management to the GC patients with HER2-positive [13, 14]. This evidence concerns the gene ERBB2 and breast cancer.